Ardelyx, Inc. ARDX 深 沪
等待开盘 01-29 09:30:00 美东时间
7.86
-0.030
-0.38%
华盛通- 最 高8.06
- 今 开7.84
- 成交量 307.18万股
- 最 低 7.70
- 昨 收 7.89
- 总市值 18.94亿
- 52周最高 8.40
- 市盈率 静 --
- 换手率 1.27%
- 52周最低 3.21
- 委 比 55.77%
- 总股本 2.41亿
- 历史最高 35.48
- 量 比 0.69
- 振 幅 4.56%
- 历史最低 0.49
- 每 手 1
- 风险率 0.98%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 奈飞绩后遭13家大行下调目标价；齐昂银行、美国合众银行获多家机构上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从9美元升至50美元；韦德布什：维持Ardelyx, Inc."跑赢大市"评级，目标价从16美元升至19美元
01-22 15:09
Lam Research To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a comple...
01-21 22:05
Wedbush Maintains Outperform on Ardelyx, Raises Price Target to $19
Wedbush analyst Laura Chico maintains Ardelyx (NASDAQ:ARDX) with a Outperform and raises the price target from $16 to $19.
01-21 21:50
美股大行评级 | 瑞穗上调英伟达、谷歌、美光科技、SanDisk多家科技股目标价；中金首予诺和诺德"跑赢大市"评级，目标价73.5美元
今日重点评级关注：Needham：维持Cartesian Therapeutics"买入"评级，目标价从40美元升至42美元；Piper Sandler：维持Acrivon Therapeutics"超配"评级，目标价从6美元升至8美元
01-12 14:09
BTIG Maintains Buy on Ardelyx, Raises Price Target to $17
BTIG analyst Julian Harrison maintains Ardelyx (NASDAQ:ARDX) with a Buy and raises the price target from $14 to $17.
01-09 18:02
美股牛股 | 获FDA支持加速药物上市！MoonLake大涨27%；Satellogic大涨21.7%
获FDA支持加速药物上市！MoonLake大涨27%；宣布获七位数地球观测合同，Satellogic涨超21%>>
01-09 16:01
Ardelyx Reports ~$378M In 2025 Product Revenue; IBSRELA Delivers $274M, Up 73% YoY; IBSRELA Guided To $410M-$430M In 2026, $1B By 2029; XPHOZAH Posts $104M In 2025 Revenue; FY26 XPHOZAH Revenue Is Expected To Be Between $110M-$120M
Company achieved significant commercial progress in 2025, generating approximately $378 million in product revenue1 IBSRELA achieved $274 million in revenue in 2025, representing 73% growth vs. 20241 IBSRELA expected to achieve $410-430 million in revenue in 2026 IBSRELA revenue expected to reach $1 billion in 2029
01-08 21:35
Ardelyx Reports Preliminary 2025 Revenue and Provides 2026 Strategic Outlook
Ardelyx reported $378 million in total product revenue for 2025, with IBSRELA generating $274 million, up 73% from 2024. IBSRELA is projected to reach $410-430 million in 2026 and $1 billion by 2029. The company also highlighted its strong cash position of $265 million and ongoing pipeline advancements, including a Phase 3 trial for IBSRELA in chronic idiopathic constipation.
01-08 13:30
Ardelyx rises amid report on price hikes for lead product
Shares of Ardelyx (ARDX) added ~8% on Friday after Bloomberg quoted a Raymond James analyst reporting that the company has implemented price increases for its lead product, tenapanor, marketed as Ibsr...
01-03 01:21
Ardelyx Presents Data, Including Results From First Real-World Study Of XPHOZAH, At ASN Kidney Week
Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that
2025-11-08 05:06
